MedTech Strategist Market Pathways explores the people, challenges, and opportunities impacting the medtech regulatory and reimbursement community. Explore our coverage. Think Strategically. Subscribe Today .
The agency’s End-Stage Renal Disease Treatment Choices (ETC) Model, set to launch January 1, will impact approximately 30% of kidney care providers for an estimated $23 million cost savings over the next few years. David White of the American Society of Nephrology discusses the model’s positives and challenges, particularly with the added impact of COVID-19.
A Medtronic device underwent a “joint” FDA-Health Canada premarket review last year as the first phase of a pilot project that the agencies hope will serve as a platform for a broader global Medical Device Single Review Program.
The agency’s End-Stage Renal Disease Treatment Choices (ETC) Model, set to launch January 1, will impact approximately 30% of kidney care providers for an estimated $23 million cost savings over the next few years. David White of the American Society of Nephrology discusses the model’s positives and challenges, particularly with the added impact of COVID-19.